Literature DB >> 10401880

No teratogenic effect after clotrimazole therapy during pregnancy.

A E Czeizel1, M Tóth, M Rockenbauer.   

Abstract

We evaluated the potential teratogenic effects of vaginal and/or topical administration of clotrimazole in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities (1980-1992). The dataset included 18,515 case pregnancies and 32,804 control pregnancies; 7.1% of case and 7.7% of control women used clotrimazole during pregnancy. Clotrimazole use was not clearly associated with an increase in the total (fetal + birth) prevalence of any congenital abnormality group. There was, however, a suggestion that clotrimazole use was associated with a decrease in the prevalence of undescended testis (prevalence odds ratio = 0.72; 95% confidence interval = 0.54-0.95).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10401880     DOI: 10.1097/00001648-199907000-00013

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  7 in total

1.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

2.  Computational discovery of therapeutic candidates for preventing preterm birth.

Authors:  Brian L Le; Sota Iwatani; Ronald J Wong; David K Stevenson; Marina Sirota
Journal:  JCI Insight       Date:  2020-02-13

3.  Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).

Authors:  Alex Farr; Isaak Effendy; Brigitte Frey Tirri; Herbert Hof; Peter Mayser; Ljubomir Petricevic; Markus Ruhnke; Martin Schaller; Axel P A Schäfer; Birgit Willinger; Werner Mendling
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-04-14       Impact factor: 2.915

4.  Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open-label pilot randomized controlled trial.

Authors:  Christine L Roberts; Kristen Rickard; George Kotsiou; Jonathan M Morris
Journal:  BMC Pregnancy Childbirth       Date:  2011-03-11       Impact factor: 3.007

5.  Risk and benefit of drug use during pregnancy.

Authors:  Ferenc Bánhidy; R Brian Lowry; Andrew E Czeizel
Journal:  Int J Med Sci       Date:  2005-07-01       Impact factor: 3.738

Review 6.  Treatment of vaginal candidiasis for the prevention of preterm birth: a systematic review and meta-analysis.

Authors:  Christine L Roberts; Charles S Algert; Kristen L Rickard; Jonathan M Morris
Journal:  Syst Rev       Date:  2015-03-21

7.  Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study.

Authors:  Yanmin Zhu; Brian T Bateman; Kathryn J Gray; Sonia Hernandez-Diaz; Helen Mogun; Loreen Straub; Krista F Huybrechts
Journal:  BMJ       Date:  2020-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.